Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31400232 | 0.91 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL1609497 | 0.91 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL546147 | 0.89 | METAP1 (0.57) | ALDH1A1SMN1; SMN2MAPTKDM4ERAB9A | |
| SCHEMBL29633503 | 0.89 | METAP1 (0.57) | ALDH1A1SMN1; SMN2MAPTKDM4ERAB9A | |
| SCHEMBL27913248 | 0.87 | PARP1 (0.47) | ALDH1A1SMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL21694418 | 0.86 | METAP1 (0.52) | ALDH1A1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL6905059 | 0.84 | MAOA (0.67) | ALDH1A1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL22738419 | 0.84 | METAP1 (0.53) | ALDH1A1SMN1; SMN2MAPTKDM4ERAB9A | |
| SCHEMBL5016641 | 0.84 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL18582934 | 0.84 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2MAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| CN-118900820-A | Liquid organohydrogen carrier compositions comprising a mixture of benzyltoluene isomers and methods of storing and releasing hydrogen using the same | 汉阳大学校产学协力团 | 2024-11-05 | — | — | CN | disclosed |
| US-10640711-B2 | Multistage thermolysis method for safe and efficient conversion of treated wood waste sources | CHZ TECHNOLOGIES, LLC (US) | 2020-05-05 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8110294-B2 | Fluorene compound; steric hindrance | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20080200736-A1 | MATERIAL FOR ORGANIC LIGHT-EMITTING ELEMENT AND ORGANIC LIGHT-EMITTING ELEMENT INCLUDING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2008-08-21 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200736-A1 | MATERIAL FOR ORGANIC LIGHT-EMITTING ELEMENT AND ORGANIC LIGHT-EMITTING ELEMENT INCLUDING THE SAME | LEF1, FMNL1, AFF1 | ALDH1A1 319/4885SMN1; SMN2 2519/4885MAPT 917/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885SMN1; SMN2 3985/4885MAPT 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.